Dupilumab in Eosinophilic Gastritis

Inclusion Criteria

• Participant and/or parent guardian must be able to understand and provide informed consent and/or assent.
• Willing and able to comply with study visits and activities
• Age ≥ 12 and 10 mg for any reason or steroid burst for > 3 days within 1 month of screening.
• Prior exposure to dupilumab.
• History of anaphylaxis to any biologic therapy.
• Current pregnancy or breastfeeding.
• Ocular disorder.
• Individuals who have required use of a systemic corticosteroid for asthma.
• Received live vaccine 30 days prior to screening or planning on receiving a live vaccine during the time period that he/she is participating in the study.
• Any esophageal stricture unable to be passed with a standard, diagnostic upper endoscope.
• History of bleeding disorders or esophageal varices.
• Active parasitic infection.
• History of alcohol or drug abuse within 6 months prior to screening.
• Participant or his/her immediate family is a member of the investigational team.
• Planned or anticipated major surgical procedure during the study.
• Initiation, discontinuation or addition of allergens to subcutaneous immunotherapy (SCIT) within 12 months prior to screening.
• Treatment with sublingual immunotherapy (SLIT) within 6 months prior to screening.
• Treatment with oral immunotherapy (OIT) within 6 months prior to screening.
• Chronic or acute infection requiring treatment with systemic antibiotics, antivirals or antifungals within 2 weeks before the baseline visit
• Known or suspected immunodeficiency disorder, including human immunodeficiency disorder (HIV).
• Planned or anticipated use of any prohibited medications and procedures during the study.
• Initiation, discontinuation or change in the dosage regimen of the following Proton pump inhibitors (PPIs) Leukotriene inhibitors Nasal and/or inhaled corticosteroids
• Women of childbearing potential who are unwilling to practice highly effective contraception.